|Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial|
AF Hernandez, JB Green, S Janmohamed, RB D'Agostino Sr, CB Granger, ...
The Lancet 392 (10157), 1519-1529, 2018
|Angiotensin–neprilysin inhibition in acute decompensated heart failure|
EJ Velazquez, DA Morrow, AD DeVore, CI Duffy, AP Ambrosy, ...
New England Journal of Medicine 380 (6), 539-548, 2019
|Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes|
KS Shah, H Xu, RA Matsouaka, DL Bhatt, PA Heidenreich, AF Hernandez, ...
Journal of the American College of Cardiology 70 (20), 2476-2486, 2017
|Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry|
SJ Greene, J Butler, NM Albert, AD DeVore, PP Sharma, CI Duffy, CL Hill, ...
Journal of the American College of Cardiology 72 (4), 351-366, 2018
|Association of the hospital readmissions reduction program implementation with readmission and mortality outcomes in heart failure|
A Gupta, LA Allen, DL Bhatt, M Cox, AD DeVore, PA Heidenreich, ...
JAMA cardiology 3 (1), 44-53, 2018
|Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from Diuretic Optimization Strategy Evaluation in Acute Decompensated …|
A Lala, SE McNulty, RJ Mentz, SM Dunlay, JM Vader, OF AbouEzzeddine, ...
Circulation: Heart Failure 8 (4), 741-748, 2015
|Trends in 30-day readmission rates for patients hospitalized with heart failure: findings from the get with the guidelines-heart failure registry|
KE Bergethon, C Ju, AD DeVore, NC Hardy, GC Fonarow, CW Yancy, ...
Circulation: Heart Failure 9 (6), e002594, 2016
|Titration of medical therapy for heart failure with reduced ejection fraction|
SJ Greene, GC Fonarow, AD DeVore, PP Sharma, M Vaduganathan, ...
Journal of the American College of Cardiology 73 (19), 2365-2383, 2019
|Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial|
M Szarek, HD White, GG Schwartz, M Alings, DL Bhatt, VA Bittner, ...
Journal of the American College of Cardiology 73 (4), 387-396, 2019
|Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY …|
KK Ray, HM Colhoun, M Szarek, M Baccara-Dinet, DL Bhatt, VA Bittner, ...
The lancet Diabetes & endocrinology 7 (8), 618-628, 2019
|Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure|
RJ Mentz, SR Stevens, AD DeVore, A Lala, JM Vader, OF AbouEzzeddine, ...
JACC: Heart Failure 3 (2), 97-107, 2015
|Trends in noncardiovascular comorbidities among patients hospitalized for heart failure: insights from the Get With the Guidelines–Heart Failure Registry|
A Sharma, X Zhao, BG Hammill, AF Hernandez, GC Fonarow, GM Felker, ...
Circulation: Heart Failure 11 (6), e004646, 2018
|Initiation, continuation, or withdrawal of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with …|
LG Gilstrap, GC Fonarow, AS Desai, L Liang, R Matsouaka, AD DeVore, ...
Journal of the American Heart Association 6 (2), e004675, 2017
|Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial|
AD DeVore, S McNulty, F Alenezi, M Ersboll, JM Vader, JK Oh, G Lin, ...
European journal of heart failure 19 (7), 893-900, 2017
|Association of 30-day readmission metric for heart failure under the hospital readmissions reduction program with quality of care and outcomes|
A Pandey, H Golwala, H Xu, AD DeVore, R Matsouaka, M Pencina, ...
JACC: Heart Failure 4 (12), 935-946, 2016
|Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get With The Guidelines–Heart Failure registry|
JB Echouffo-Tcheugui, H Xu, AD DeVore, PJ Schulte, J Butler, CW Yancy, ...
American heart journal 182, 9-20, 2016
|Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsartan or enalapril in the PIONEER-HF trial|
DA Morrow, EJ Velazquez, AD DeVore, AS Desai, CI Duffy, AP Ambrosy, ...
Circulation 139 (19), 2285-2288, 2019
|Body weight change during and after hospitalization for acute heart failure: patient characteristics, markers of congestion, and outcomes: findings from the ASCEND-HF trial|
AP Ambrosy, LP Cerbin, PW Armstrong, J Butler, A Coles, AD DeVore, ...
JACC: Heart Failure 5 (1), 1-13, 2017
|Timing and causes of readmission after acute heart failure hospitalization—insights from the Heart Failure Network Trials|
JM Vader, SJ LaRue, SR Stevens, RJ Mentz, AD DeVore, A Lala, ...
Journal of cardiac failure 22 (11), 875-883, 2016
|Torsemide versus furosemide in patients with acute heart failure (from the ASCEND-HF Trial)|
RJ Mentz, V Hasselblad, AD DeVore, M Metra, AA Voors, PW Armstrong, ...
The American journal of cardiology 117 (3), 404-411, 2016